Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunction.

Pistilli EE, Bogdanovich S, Mosqueira M, Lachey J, Seehra J, Khurana TS.

Am J Physiol Regul Integr Comp Physiol. 2010 Jan;298(1):R96-R103. doi: 10.1152/ajpregu.00138.2009. Epub 2009 Oct 28.

2.

Mitochondrial impairment induced by postnatal ActRIIB blockade does not alter function and energy status in exercising mouse glycolytic muscle in vivo.

Béchir N, Pecchi É, Relizani K, Vilmen C, Le Fur Y, Bernard M, Amthor H, Bendahan D, Giannesini B.

Am J Physiol Endocrinol Metab. 2016 Apr 1;310(7):E539-49. doi: 10.1152/ajpendo.00370.2015. Epub 2016 Feb 2.

3.

Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy.

Pistilli EE, Bogdanovich S, Goncalves MD, Ahima RS, Lachey J, Seehra J, Khurana T.

Am J Pathol. 2011 Mar;178(3):1287-97. doi: 10.1016/j.ajpath.2010.11.071.

4.

Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice.

Hulmi JJ, Oliveira BM, Silvennoinen M, Hoogaars WM, Pasternack A, Kainulainen H, Ritvos O.

Am J Physiol Endocrinol Metab. 2013 Jul 15;305(2):E171-82. doi: 10.1152/ajpendo.00065.2013. Epub 2013 May 21.

5.

ActRIIB blockade increases force-generating capacity and preserves energy supply in exercising mdx mouse muscle in vivo.

Béchir N, Pecchi E, Vilmen C, Le Fur Y, Amthor H, Bernard M, Bendahan D, Giannesini B.

FASEB J. 2016 Oct;30(10):3551-3562. Epub 2016 Jul 14.

6.

Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.

Puolakkainen T, Ma H, Kainulainen H, Pasternack A, Rantalainen T, Ritvos O, Heikinheimo K, Hulmi JJ, Kiviranta R.

BMC Musculoskelet Disord. 2017 Jan 19;18(1):20. doi: 10.1186/s12891-016-1366-3.

7.

Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice.

Hoogaars WM, Mouisel E, Pasternack A, Hulmi JJ, Relizani K, Schuelke M, Schirwis E, Garcia L, Ritvos O, Ferry A, 't Hoen PA, Amthor H.

Hum Gene Ther. 2012 Dec;23(12):1269-79. doi: 10.1089/hum.2012.056. Epub 2012 Sep 24.

PMID:
22894762
8.

Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents.

Chiu CS, Peekhaus N, Weber H, Adamski S, Murray EM, Zhang HZ, Zhao JZ, Ernst R, Lineberger J, Huang L, Hampton R, Arnold BA, Vitelli S, Hamuro L, Wang WR, Wei N, Dillon GM, Miao J, Alves SE, Glantschnig H, Wang F, Wilkinson HA.

J Gerontol A Biol Sci Med Sci. 2013 Oct;68(10):1181-92. doi: 10.1093/gerona/glt030. Epub 2013 Mar 22.

PMID:
23525481
9.

A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health.

Koncarevic A, Cornwall-Brady M, Pullen A, Davies M, Sako D, Liu J, Kumar R, Tomkinson K, Baker T, Umiker B, Monnell T, Grinberg AV, Liharska K, Underwood KW, Ucran JA, Howard E, Barberio J, Spaits M, Pearsall S, Seehra J, Lachey J.

Endocrinology. 2010 Sep;151(9):4289-300. doi: 10.1210/en.2010-0134. Epub 2010 Jun 23.

PMID:
20573726
10.

Activin type IIB receptor blockade does not limit adenosine triphosphate supply in mouse skeletal muscle in Vivo.

Béchir N, Pecchi É, Vilmen C, Bernard M, Bendahan D, Giannesini B.

Muscle Nerve. 2018 Dec;58(6):834-842. doi: 10.1002/mus.26306.

PMID:
30025155
11.

Gene expression profiling of skeletal muscles treated with a soluble activin type IIB receptor.

Rahimov F, King OD, Warsing LC, Powell RE, Emerson CP Jr, Kunkel LM, Wagner KR.

Physiol Genomics. 2011 Apr 27;43(8):398-407. doi: 10.1152/physiolgenomics.00223.2010. Epub 2011 Jan 25.

12.

Soluble activin receptor type IIB decoy receptor differentially impacts murine osteogenesis imperfecta muscle function.

Jeong Y, Daghlas SA, Kahveci AS, Salamango D, Gentry BA, Brown M, Rector RS, Pearsall RS, Phillips CL.

Muscle Nerve. 2018 Feb;57(2):294-304. doi: 10.1002/mus.25706. Epub 2017 Jun 15.

13.

Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist.

Toledo M, Busquets S, Penna F, Zhou X, Marmonti E, Betancourt A, Massa D, López-Soriano FJ, Han HQ, Argilés JM.

Int J Cancer. 2016 Apr 15;138(8):2021-9. doi: 10.1002/ijc.29930. Epub 2015 Dec 9.

14.

Activin Receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy.

Liu M, Hammers DW, Barton ER, Sweeney HL.

PLoS One. 2016 Nov 21;11(11):e0166803. doi: 10.1371/journal.pone.0166803. eCollection 2016.

15.

A novel therapeutic approach to treating obesity through modulation of TGFβ signaling.

Koncarevic A, Kajimura S, Cornwall-Brady M, Andreucci A, Pullen A, Sako D, Kumar R, Grinberg AV, Liharska K, Ucran JA, Howard E, Spiegelman BM, Seehra J, Lachey J.

Endocrinology. 2012 Jul;153(7):3133-46. doi: 10.1210/en.2012-1016. Epub 2012 May 1.

16.

Myostatin/activin blocking combined with exercise reconditions skeletal muscle expression profile of mdx mice.

Kainulainen H, Papaioannou KG, Silvennoinen M, Autio R, Saarela J, Oliveira BM, Nyqvist M, Pasternack A, 't Hoen PA, Kujala UM, Ritvos O, Hulmi JJ.

Mol Cell Endocrinol. 2015 Jan 5;399:131-42. doi: 10.1016/j.mce.2014.10.001. Epub 2014 Oct 7.

PMID:
25304272
17.

The effects of an ActRIIb receptor Fc fusion protein ligand trap in juvenile simian immunodeficiency virus-infected rhesus macaques.

O'Connell KE, Guo W, Serra C, Beck M, Wachtman L, Hoggatt A, Xia D, Pearson C, Knight H, O'Connell M, Miller AD, Westmoreland SV, Bhasin S.

FASEB J. 2015 Apr;29(4):1165-75. doi: 10.1096/fj.14-257543. Epub 2014 Dec 2.

18.
19.

Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy.

Morine KJ, Bish LT, Selsby JT, Gazzara JA, Pendrak K, Sleeper MM, Barton ER, Lee SJ, Sweeney HL.

Muscle Nerve. 2010 Nov;42(5):722-30. doi: 10.1002/mus.21743.

20.

Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.

Morvan F, Rondeau JM, Zou C, Minetti G, Scheufler C, Scharenberg M, Jacobi C, Brebbia P, Ritter V, Toussaint G, Koelbing C, Leber X, Schilb A, Witte F, Lehmann S, Koch E, Geisse S, Glass DJ, Lach-Trifilieff E.

Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12448-12453. doi: 10.1073/pnas.1707925114. Epub 2017 Nov 6.

Supplemental Content

Support Center